Saratov JOURNAL of Medical and Scientific Research

Assessment of the effect of liposomal forms of Xymedon and Mexidol® on the therapeutic effect of liposomal antineoplastic drugs in the experiment

Year: 2021, volume 17 Issue: №4 Pages: 780-786
Heading: Parmacology Article type: Original article
Authors: Siprov A.V., Solovyova M.A., Ageev V.P., Vashurkina I.M., Shubin D.Yu., Kechemaykina M.I.
Organization: National Research Ogarev Mordovia State University, Institute of Medicine

Our aim is the assessment of effect of liposomal forms of Xymedon and Mexidol on antitumor and antimetastatic efficiency of liposomal combination «doxorubicin/cyclophosphamide» in experimental rats with Walker-256 carcinoma. Material and methods. Experiments were carried out on 116 Wistar female rats of weight 170-270 gm. «Doxorubicin/cyclophosphamide» combination at doses of 4/45 mg/kg, respectively, was administered as a free and liposomal forms intravenously on day 11th day of the experiment. Free and liposomal forms of Xymedon (50 and 100 mg/kg) and Mexidol (25 and 50 mg/kg) were administered intravenously during 5 days starting with day 11 of the experiment. Results. Liposomal form of Xymedon and Mexidol in the studied doses doesn't affect the growth dynamics and mass of primary tumor and doesn't prevent its metastasis suppression at the use of liposomal combination «doxorubicin/cyclophosphamide» in rats with Walker-256 carcinoma. The disappearance of large lung metastases (more than 1 mm in diameter) and predominance of small lung metastases (less than 1 mm in diameter) were observed at the combined use of liposomal Xymedon and Mexidol in the studied doses with liposomal cytostatics. Conclusion. The use of liposomal Xymedon and Mexidol together with chemotherapy by «doxorubicin/cyclophosphamide» liposomal combination doesn't reduce the therapeutic efficiency of these cytostatics and is manifested by the absence of significant changes of slowing down the growth of the primary tumor and its metastasis in rats with Walker-256 carcinoma.

1. Lozovska YuV, Andrusishina IM, Lukianova NYu, et al. The influence of lactoferrin on elemental homeostasis and activity of metal-containing enzymes in rats with Walker-256 carcinosarcoma. Experimental Oncology 2019; 41 (1): 20-5.
2. Pobiarzhyn VV, Pashinskaya YeS, Semenov VM, HoncharovAYe. Methodological aspects of setting up oncological models under experimental conditions. Vestnik of Vitebsk State Medical University 2018; 17 (6): 32-45.
3. Singh К, Bhori М, Kasu YA, et al. Antioxidants as precision weapons in war against cancer chemotherapy induced toxicity — Exploring the armoury of obscurity. Saudi Pharm J 2018; 26 (2): 177-90. DOI: 10.1016/j. jsps.2017.12.013.
4. Watson J. Oxidants, antioxidants and the current incurability of metastatic cancers. Open Biol 2013; 3 (1): 120144. DOI: 10.1098/rsob.120144.
5. Piskounova E, Agathocleous M, Murphy MM, et al. Oxidative stress inhibits distant metastasis by human melanoma cells. Nature 2015; 527 (7577): 186-91. DOI: 10.1038/nature15726.
6. Hawk MA, McCallister C, Schafer ZT. Antioxidant activity during tumor progression: a necessity for the survival of cancer cells? Cancers (Basel) 2016; 8 (10): 92. DOI: 10.3390/cancers8100092.
7. Yun J, Mullarky E, Lu C, et al. Vitamin С selectively kills KRAS and BRAF mutant colorectal cancer cells by targeting GAPDH. Science 2015; 350 (6266): 1391-6. DOI: 10.1126/science.aaa5004.
8. Butdak RJ, Pilc-Gumuta K, Butdak t, et al. Effects of ghrelin, leptin and melatonin on the levels of reactive oxygen species, antioxidant enzyme activity and viability of the HCT 116 human colorectal carcinoma cell line. Mol Med Rep 2015; 12 (2): 2275-82. DOI: 10.3892/mmr.2015.3599.
9. Kim J-H, Jeong S-J, Kim B, et al. Melatonin synergistically enhances cisplatin-induced apoptosis via the dephosphorylation of ERK/p90 ribosomal S6 kinase/heat shock protein 27 in SK-OV-3 cells. J Pineal Res 2012; 52 (2): 244-52.
10. Masyagin VA. The effect of hydroxyethyldimethyldihydro pyrimidine and its combination with ethylmethylhydroxypyridine succinate on the hemato- and myelotoxicity of antitumor chemotherapy in experiment: PhD abstract. Moscow, 2017; 25 p.
11. Mut-Salud N, Alvarez PJ, Garrido JM, et al. Antioxidant intake and antitumortherapy: toward nutritional recommendations for optimal results. Oxid Med Cell Longev 2016; (2016): 6719534. DOI: 10.1155/2016/6719534.
12. Khabriev RU. Guidelines for experimental (preclinical) study of new pharmacological substances. Moscow: Meditsina, 2005; 832 p.
13. Shvets VI, Lyutik Al. The research applicable to elaboration of new generation of effective medicinal drugs using encapsulation of classic substances into nanocontainers. Fine Chemical Technologies 2014; 9(3): 11-20.

2021_04_780-786.pdf768.22 KB

No votes yet